

Literatur zum Artikel

Neue Substanzen für die Therapie des fortgeschrittenen NSCLC

1. Barlesi, F, Mazieres, J, Merlio, J-P, et al (2016) Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). *Lancet* 387(10026): 1415–1426
2. Yang JC, Wu YL, Schuler M, et al (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol* 16: 141–151.
3. Park K, Tan E-H, O'Byrne K, et al (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. *Lancet Oncol* 17: 577–589
4. Yang JC, Sequist LV, Geater SL, et al (2015) Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. *Lancet Oncol* 16: 830–838
5. Arrieta O, Vega-González MT, López-Macías D, et al (2015) Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients. *Lung Cancer* 88: 282–288
6. Jänne P, Yang J, Kim D-W, et al (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N Engl J Med* 372: 1689–1699
7. Yang J, Ramalingam SS, Jänne PA, et al (2016) LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. *J Thorac Oncol* 11(4 Suppl): S152–S153
8. Wakelee H, Gadgeel S, Goldman JW, et al (2016) Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. *J Clin Oncol* 34(Suppl): abstr 9001
9. Solomon B, Mok T, Kim D-W, et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med* 371: 2167–2177
10. Costa D, Shaw A, Ou S-H, et al (2015) Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. *J Clin Oncol* 33: 1881–1888
11. Nokihara H, Hida T, Kondo M, et al (2016) Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from the J-ALEX study. *J Clin Oncol* 34(Suppl): abstr 9008
12. Shaw AT, Kim DW, Mehra R, et al (2014) Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med* 370: 1189–1197
13. Scagliotti GV, Parikh P, von Pawel J, et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol* 26: 3543–3551
14. Thatcher N, Hirsch FR, Luft AV, et al (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. *Lancet Oncol* 16: 763–774
15. Paz-Ares L, Mezger J, Ciuleanu TE, et al (2015) Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. *Lancet Oncol* 16: 328–337
16. Reck M, Kaiser R, Mellemegaard A, et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. *Lancet Oncol* 15: 143–155
17. Garon EB, Ciuleanu T-E, MD, Arrieta O, et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. 384(9944): 665–673
18. Soria JC, Felip E, Cobo M, et al (2015) Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. *Lancet Oncol* 16: 897–907
19. Borghaei H, Paz-Ares L, Horn L, et al (2015) Nivolumab versus docetaxel in advanced non-squamous non-small-cell lung cancer. *N Engl J Med* 373: 1627–1639
20. Brahmer J, Reckamp K, Baas P, et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med* 373: 123–135
21. Borghaei H, Brahmer J, Horn L et al (2016) Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. *J Clin Oncol* 34(Suppl) abstr 9025